IDBS announced as a National Technology Awards finalist

Published on:
Guildford, UK, March 14, 2017 – Today IDBS, a leading R&D and scientific software solutions provider, has been recognized by the National Technology Awards for its innovative cloud solutions, which enable the world’s leading research organizations to operate faster and more effectively.
 Laurence Painell, Vice President of Marketing at IDBS said: “IDBS’ recognition by the National Technology Awards showcases our commitment to continuously improving our services and standout cloud offering. The IDBS E-WorkBook Cloud shortlist as Cloud Product of the Year is a testament to our drive to create innovative software solutions to the world’s most prominent R&D and scientific research challenges.”
 The National Technology Awards, hosted by FStech Magazine, celebrates the leaders of pioneering technology. The National Technology Awards were created to allow the technology sector to shine, celebrating the innovators of new technology and to help drive standards and encourage excellence.
 The winners will be determined by an independent judging panel and announced at the National Technology Awards Gala and Dinner on 17 May 2017 at the Millennium Hotel London Mayfair.

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.